Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.

Pharmacogenomics - 1 Jul 2017

Maroofi Nahal, Azarkeivan Azita, Banihashemi Soosan, Mohammadparast Saeid, Aghajanirefah Ali, Banan Mehdi

Abstract excerpt

AIM: To identify the BCL11A intron-2 enhancer linkage disequilibrium (LD) block, harboring two previously identified SNPs, associating with the hydroxyurea response in β-thalassemia patients and the functional significance of this region. MATERIALS & METHODS: Several neighboring SNPs were genotyped in our cohort. The associating LD block was identified, and its function studied in K562 erythroid cells via...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Repressor Proteins
Share to beta-Thalassemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer Elements, Genetic

Share to HEK293 Cells

Share to Hydroxyurea

Share to K562 Cells

Share to Pharmacogenomic Variants

Share to Reticulocytes

Source

Identifiers

PMID: 28639471
DOI: 10.2217/pgs-2017-0019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.PMID 28639471Read ↗

An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level.Semantic proximity Read ↗

Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical ApplicationsSemantic proximity Read ↗

Hydroxyurea down‐regulates <i>BCL11A, KLF</i>‐<i>1</i> and <i>MYB</i> through miRNA‐mediated actions to induce γ‐globin expression: implications for new therapeutic approaches of sickle cell diseaseSemantic proximity Read ↗

Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia.Semantic proximity Read ↗

BCL11A enhancer haplotypes and fetal hemoglobin in sickle cell anemia.Semantic proximity Read ↗

Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.Semantic proximity Read ↗

Clinical-Scale Genome Editing of the Human BCL11A Erythroid Enhancer for Treatment of the HemoglobinopathiesSemantic proximity Read ↗

KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.Semantic proximity Read ↗

Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11ASemantic proximity Read ↗

Multiplex base editing of <i>BCL11A</i> regulatory elements to treat sickle cell diseaseSemantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

Transcriptional silencing of fetal hemoglobin by BCL11ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.